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Abstract
Senescence and mitotic catastrophe (MC) are two distinct crucial non-apoptotic mechanisms, often triggered in
cancer cells and tissues in response to anti-cancer drugs. Chemotherapeuticals and myriad other factors induce cell
eradication via these routes. While senescence drives the cells to a state of quiescence, MC drives the cells towards
death during the course of mitosis. The senescent phenotype distinguishes tumor cells that survived drug expo-
sure but lost the ability to form colonies from those that recover and proliferate after treatment. Although senes-
cent cells do not proliferate, they are metabolically active and may secrete proteins with potential tumor-
promoting activities. The other anti-proliferative response of tumor cells is MC that is a form of cell death that
results from abnormal mitosis and leads to the formation of interphase cells with multiple micronuclei. Different
classes of cytotoxic agents induce MC, but the pathways of abnormal mitosis differ depending on the nature of
the inducer and the status of cell-cycle checkpoints. In this review, we compare the two pathways and mention
that they are activated to curb the growth of tumors. Altogether, we have highlighted the possibilities of the use
of senescence targeting drugs, mitotic kinases and anti-mitotic agents in fabricating novel strategies in cancer
control.
Introduction
The incidence of cancer worldwide is on a rise, making it
only second to coronary heart disease [1]. Unifying prop-
erty of cancer includes six canonical characteristics: self
sufficiency in growth signals, insensitivity to growth inhibi-
tory signals (anti-growth), evasion of programmed cell
death (apoptosis), unlimited proliferation of diseased cells,
sustained angiogenesis, intrusion of adjacent cells and tis-
sues and metastasis to distant niches in the body [2].
Genetic instability associated with telomere attrition
or cell cycle checkpoint dysfunction is an early event in
tumorigenesis. Telomeres are guanine rich tandem
nucleotide repeats flanking the ends of chromosomes in
all eukaryotic cells responsible for maintaining genetic
integrity and implicated in aging (senescence) and can-
cer [3]. Cell cycle checkpoints or mitotic kinases (MKs)
are the rigorous quality control steps of mitosis [4] that
function in preserving the fidelity and integrity of DNA
and allow mitosis to continue with accurately function-
ing DNA, spindle assembly, centrosome and kinetochore
thus preventing cell death via mitotic catastrophe (MC).
MC therefore, refers to the process when cells attempt
to divide without proper repair of DNA damage due to
faulty cell cycle checkpoint functioning consequently
resulting in formation of giant, multinucleated cells with
condensed chromosomes, distinguishing MC morpholo-
gically from other modes of cell deaths.
Abundant data amassed from several laboratories have
provided innumerable instances to show that it is better
to cure this dreadful disease at preventable stage by
early diagnosis and consequent therapeutic intervention.
Strategies for cancer treatment has generated significant
interest in the recent past and therefore, the focus of
research endeavors on understanding the mechanism of
cell death pathways applicable in treatment of cancer
which include not only apoptosis but necrosis, autop-
hagy, MC and in context of cancer therapy, senescence
has always been there [5].
This review will explore major highlights on the role
of senescence and MC triggered in various cancers by
chemotherapeutic intrusion and opens avenues for
expanding research work by comparing the results
obtained so far.
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The term senescence is derived from the Latin word
senex, meaning “old age” or “advanced in age”.S e n e s -
cence at the cellular level is a physiological program of
cellular growth arrest that is triggered by the shortening
of telomeres or by stress [6]. This permanent growth
arrest is also considered a type of cell death in the con-
text of cancer therapy by some researchers [7,8] and
some consider it similar to the programmed cell death
by ‘apoptosis’ [9]. Senescence can be broadly categorized
into two classes: accelerated or stress induced premature
senescence (SIPS) and replicative senescence (RS) and
both are believed to be essential anti-carcinogenic pro-
grams in normal cells. Accelerated senescence occurs in
response to the activation of Ras/Raf pathways [10] and
by supra-physiological mitogenic signaling [11]. The
phenomenon of RS was first described in the context of
normal human cells explanted in culture that failed to
divide beyond a finite number of fifty divisions [12] and
it is a well-known defining property of euploid mamma-
lian cells [13]. Telomere dynamics has been shown to be
a critical component of both aging and cancer [14]. Tel-
omeres, the highly repetitive DNA (TTAGGG sequence)
which camouflages chromosome ends [15] prevent
nucleolytic degradation, end-to-end fusion, irregular
recombination, and other events that are normally lethal
to a cell [15]. With each cell division a part of telomere
gets eroded [16,17] and the chromosome being passed
to the progeny gets the clipped off telomere.
Thus genetic integrity is gradually lost with telomeres
progressively shortening after each division as a result of
end-replication problems and hence, is a conspicuous
feature in almost all dividing cells which do not express
or maintain sufficient telomerase activity to maintain
the telomeres. Telomerase reverse transcriptase
(hTERT), whose amount is lessened after birth, func-
tions by replenishing telomere by adding TTAGGG
sequence at the 3’end of DNA. Telomerase activity is
measured by TRAP assay or RT-PCR. Less frequently
other alternative mechanism of telomere maintenance
namely Alternative Lengthening of Telomeres (ALT) is
opted [18]. Telomere dysfunction (short telomeres) has
been associated with the initiation and progression of
mouse and human intestinal neoplasia [19] and may
also increase the risk of developing epithelial cancers by
a process of breakage-fusion-bridge that leads to the for-
mation of complex nonreciprocal translocations (a clas-
sical cytogenetic feature of human carcinoma) [20].
Blood relative telomere length was found to represent a
strong independent prognostic indicator in patients with
advanced breast cancer [21]. Similarly mean telomere
length was statistically shorter in case patients with head
and neck cancer as compared with control as measured
with the southern blot and quantitative-fluorescent in
situ hybridization assay [22]. Telomerase and p53 play
critical roles in tumorigenesis and senescence. Senescent
cells exhibit distinct morphology in culture. They are
enlarged and flattened with increased granularity [23]
exhibit SA-b-gal staining and a characteristic senescence
associated heterochromatin foci (SAHF) formation [24]
and comparatively less dense culture than a confluent
young culture probably because they are more sensitive
to cell-cell contact inhibition [12,13]. Even though they
cannot divide under mitogenic stimulation yet they
remain metabolically and synthetically active in in vitro
conditions for several years [24] but can not resume cell
growth after drug withdrawal. SA-b-gal, the most widely
used surrogate marker with considerable specificity to
senescent cells appears to reflect an increased lysosomal
mass [23]. Another marker is clusterin/apolipopterin J,
is a highly conserved ubiquitously expressed secreted
glycoprotein has been implicated in many physiological
processes, gets upregulated during stress induced pre-
mature senescence, in vivo aging, RS, in several age
linked deformities, neuropathological disorders like Alz-
hiemers disease and dementia and has a direct relation-
ship with human longevity [25]. Cellular senescence is a
potent anti-cancer mechanism controlled by tumor sup-
pressor genes, particularly p53 and pRb.
Role of p53
Telomere-induced senescence has been proved to be as
effective as apoptosis in reducing cancer incidence and
is mediated by the tumor suppressor gene, p53 [26].
Mutations in the p53 gene frequently appear in human
tumors conferring aggressive oncogenic properties such
as exacerbated malignant transformation and metastatic
phenotype when over-expressed in p53-null cells. P53
gets activated upon genotoxic and non genotoxic stres-
ses like oxidative damage and activates p21 and ulti-
mately culminates the cell to senescence. Mice with a
point mutation (p53(R172H)) in their endogenous p53
loci act as a model for the human Li-Fraumeni syn-
drome. Genetic alterations at chromosomes 3p, 6p, and
1lq were frequently found early in tumor development
and showed additional allelic losses at chromosome
arms 6q, 17p and 18q. Genes for telomerase suppression
are presumably located on chromosomes 3, 4 and 6 [27].
P53 over expression has been directly associated with
unfavorable clinico-pathologic factors such as advanced
stage, histologic subtype, advanced patient age and
nodal metastasis in endometrial carcinomas while bcl-2
expression was related with younger age, favorable grade
and PR expression by tumor cells. Patient survival is
however not related to the tested biomarkers [28]. In
humans, TP53 codon 72 Arginine to Proline poly-
morphism was found to affect both cancer incidence
and longevity as well [29]. The senescence-associated
signature of p53 isoform expression (that is, elevated
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in colon adenomas with senescent phenotypes. The
increased Delta133p53 and decreased p53beta isoform
expression found in colon carcinoma may signal an
escape from the senescence barrier during the progres-
sion from adenoma to carcinoma [30].
Other tumor suppressor genes
P107 is required for the initiation of accelerated cellular
senescence in the absence of Rb and p130 may be
required to prevent the onset of this phenomenon in un-
stimulated prostate cancer cells lacking a functional Rb
allele [31]. Cell cycle regulatory proteins are more sensi-
tive to exogenous hormone treatment in postm-HBT
(postmenopausal human breast tissue) than in pre-HBT
(premenopausal human breast tissue) [32]. Olsson et al
advocates that bfl-1 (tumor suppressor bcl-2 family
member) contributes to chemo resistance and might be a
therapeutic target in B-cell chronic lymphocytic leukae-
mia [33]. The activation of PI3K/Akt pathway is involved
in the late-stage progression and metastasis of gastric
cancer and attenuation of p-Akt by 2-ME suppresses
metastasis [34]. Yet another tumor suppressor Promyelo-
lytic leukemia (PML) regulates p53 acetylation in both
RS as well as Ras induced accelerated senescence [35].
Senescence in cancer cells: In vitro studies
A large number of in vitro studies have been reported
where a wide range of chemotherapeutical antidotes
induce senescence like morphological changes and SA-
b-gal expression in cancer cells activating the pathway
of senescence. Research into the induction of cellular
senescence as cancer therapy has however, been hin-
dered by a lack of compounds that efficiently induce
this response. To overcome this, Ewald et al (2009) by
using dual Hoechst 33342 and SA-b gal staining identi-
fied library compounds that induce senescence in pros-
tate cancer cells [36]. It is well acknowledged that
telomerase and the maintenance of telomeres are key
players in the ability of stem and cancer cells to bypass
senescence and be immortal. Proliferation of telomerase
(-) pre-malignant cells leads to telomere dysfunction
and increased genomic instability suggesting one possi-
ble sequence of events leading to immortalization of
breast epithelial cells during cancer progression [37].
T h ei n c r e a s e dh - T E R Te x p r e s s i o nm a yb eac e l l u l a r
response to genomic insults by various metal toxicants
like arsenic that may also act as a tumor promoter in
mammalian carcinogenesis as studied in blood cells by
Mumford et al hTERT-specific T cells could contribute
to the immunosurveillance of breast cancer suggests
novel opportunities for both therapeutic and prophylac-
tic vaccine strategies for cancer [38].
In one of the studies, using non-small lung adenocar-
cinoma A549 cells, it was shown that after treatment
with DNA damaging anti-tumor drugs like caffeine, cells
become permanently growth-arrested as a result of so-
called drug-induced premature senescence (pseudo-
senescence) or SIPS. Similarly, lowered efficacy of anti-
cancer doxorubicin (due to dose dependent toxicity)
against breast cancer cells can be increased when used
in conjunction with siRNA inhibitor of telomerase [39].
Yet another study advocated the use of GRN163L (novel
telomerase template antagonist) in the treatment of
breast cancer by augmenting the effects of paclitaxel
[40]. Hence clearly proposing that inhibition of telomer-
ase is a potential treatment strategy for inducing senes-
cence. It has also been shown that caveolin-1 targets
Mdm2/p53-mediated pathway and causes senescence in
breast cancer cells [41]. Another study reported that
bleomycin, a widely used anti-tumor agent, causes
senescence of lung cancer cells by modulating the roles
of caveolin-1, a protein abundant in lung fibroblasts and
smooth muscle and endothelial cells [42].
A recent study showed that the activation of the p53-
p21(Cip1/WAF1) pathway acts as a major mediator of cel-
lular senescence induced by CKII inhibition in HCT116
colon carcinoma cells [43]. A senescence-inducing effect
of doxorubicin on the same cells, in another study, had a
dual effect-it stopped the proliferation of the majority of
the cells and led to the appearance of proliferating aneu-
ploid cells [44]. Likewise, while characterizing ashwa-
gandha and its molecular mechanisms Wadhwa et al
provided the first example that phytochemical(s) have
both anti-cancer and anti senescent activities and pointed
towards the molecular link between aging and cancer
using normal human fibroblasts through decreased accu-
mulation of molecular damage, down-regulation of the
SA-b gal activity and the senescence marker protein, p21
(WAF-1), protection against oxidative damage, and induc-
tion of proteasomal activity [45]. In one of the studies, by
silencing BRCA1 expression at different levels through
RNA interference technology in a series of partially trans-
formed (HBL100) and tumorigenic (MCF7 and T47D)
breast cancer cell lines, cell models were probed by clono-
genic assay for their response to several DNA-damaging
agents (mitomycin C, cisplatin, doxorubicin, and etopo-
side) commonly used in cancer therapy [46]. The
increased sensitivity to these compounds displayed by
BRCA1-defective cells was correlated to an increased frac-
tion of growth-arrested, enlarged, multinucleated SA-b-
galactosidase-positive senescent cells [46]. Melanocytic
nevi frequently harbor oncogenic BRAF mutations and
recently it was found that a subpopulation of melanocytes
possess the ability to survive BRAF induced senescence,
and suggest that p53 inactivation may promote malignant
transformation of these cells [47] and thus have implica-
tions in skin cancer treatment. In vitro experiments with
therapeutic nucleic acids successfully inhibited E6/E7
oncogene expression and caused induction of apoptosis
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assay was described by Lau et al [48] to predict the
response of the patient to a set of medicines without
administering them by testing the susceptibility of a sam-
ple of cancer cells in vitro and comparing it to the stan-
dard regimen.
Apart from these, it has been observed that cells’ pas-
sage number controls the appearance of senescence.
Normal human diploid fibroblasts approach senescence
near passage 64 through RNaseT2 expression, which
however fails to induce senescence in SV40 immorta-
lized cell lines [49]. Rat chondrocytes show the onset of
senescence in the 4
th passage [50] while human rheuma-
toid arthritis fibroblast-like synoviocytes exhibit ageing
at 10
th passage [51]. Stable clones derived from hTERT-
expressing normal and G6PD-deficient fibroblasts have
normal karyotypes, and display no sign of senescence
beyond 145 and 105 passages, respectively, suggesting
that ectopic expression of hTERT, in addition to telo-
mere length maintenance by activating telomerase, also
functions in regulating senescence induction [52].
Recently, a study explored the self-renewal potential of
human breast stem cells and found that it gets
exhausted within five in vitro passages of mammo-
spheres, suggesting the need for further improvisation in
culture conditions for their long-term maintenance [53].
Senescence in animal models: In vivo studies
Induction of senescence upon drug administration has
been proposed as a possible anti-cancer treatment in
various animal models. The finite proliferative potential
of normal human cells leads to RS, which is a critical
barrier to tumor progression in vivo.B ys t u d y i n g
embryonic fibroblast-derived cells with loss-of-senes-
cence or H-RasV12/E1A-transformed phenotypes at dif-
ferent stages of oncogenic progression in nude mice, it
was postulated that they may escape therapies aimed at
metabolic inhibition of tumors with a fully developed
Warburg phenotype [54]. b-carotene provides protection
against O3-induced skin oxidative stress in female SKH-
1 mice skin, which is consistent with a protective role
for beta-carotene in the skin hence has implications in
skin cancer and aging or senescence of skin [55]. A
novel target of NESH-SH3 (TARSH), cellular senescence
related gene in mouse embryonic fibroblasts may sup-
press tumor development in pulmonary tumorigenesis
mouse model by causing an increase in SA-b-gal activity
and this was attributed to p53-dependent p21
(Cip1) accu-
mulation [56]. Pituitary tumor transforming gene dele-
tion results in pituitary p21 induction and abrogates
tumor development in Rb(+/-)Pttg(-/-) mice. Senescence
was evidenced by increased p21 and SA-b-galactosidase.
Aneuploid pituitary cell p21 may constrain pituitary
tumor growth, thus accounting for the very low inci-
dence of pituitary carcinomas [57]. Work by Efimova et
al using p38-null mice skin carcinogenesis model
strongly suggests a role for p38delta (key regulator in
senescence, tumorigenesis, survival, inflammation etc) in
promoting cell proliferation and tumor development in
epidermis and may have therapeutic implication for skin
cancer [58]. Three xenograft breast cancer mouse mod-
els, 2 of them with a TP53 mutation and one without it,
were studied for their immediate response to high doses
of epirubicin-cyclophosphamide. TP53 wild type stained
positive for SA-b-galactosidase staining and also over
expressed P21 but TP53 mutant did not succumb to
senescence suggesting that treatment induced senes-
cence is mediated via functional p53 in breast cancer
[59]. More in vivo studies are however, needed to eluci-
date the role of senescence in cancer. Although these
concepts are well supported in these models, translating
them to clinical oncology remains a challenge.
Neosis - Achilles heel of cancer cells evading senescence
The physiological phenomenon of senescence serves as a
lucrative pathway to annihilate deleterious cancer cells
and tissues. This program of senescence is activated upon
the administration of various anti-cancer regimens. Even
though this is not a universal mechanism of curbing
tumor cell growth, yet a considerable number of instances
of in vitro as well as in vivo studies have been cited to
decipher the metabolic pathway it targets and these stu-
dies have produced useful results that have enhanced and
refined our knowledge about these pathways (Figure 1)
and will be helpful in delineating new treatment strategies
for curtailing cancer. Several studies [60,61], however pro-
vide compelling evidence that some cancer cells which are
mitotically non-viable escape cell death, due to the accu-
mulation of some genetic and epigenetic mutations and
p53/pRB/p53
Ink4a-dependent senescence checkpoint mal-
functioning resulting in telomerase dysfunction [61,62]
and finally evade cell death via continued progression
through neosis. Such cells acquire so called’ immortality’
and to eliminate them, different strategies need to be
designed. These cells multiply by a unique route called
‘neosis’ that facilitates in its progression and existence
thereby evading the program of senescence. It has been
described as a parasexual, somatic, reduction division in
cancer [62]. Although neosis-like events have been
reported in the literature sporadically for more than a cen-
tury [63] under different names, they have been neglected
due to the lack of appreciation of the significance of this
process in cancer biology. Neosis may be a fundamental
step in current concept of multi step carcinogenesis.
Studying the behavior of individual neotic clones has
revealed the significance of their central role in cancer
[64]. Non-synchronous occurrence of secondary/tertiary-
neosis (Figure 2) creates the illusion of the existence of
cancer stem cells and the ‘mirage’ of immortality of cancer
cells.
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the achilles heel of the mutated tumors that bypass the
effect of certain classes of anti-cancer agents. That is,
patients whose tumors carry such defects can be strati-
fied for respective therapy rendering some classic DNA
damaging agents called neosicides into “targeted thera-
pies.” Development of novel strategies to improve cur-
rent status of cancer therapy will require identification
and exploitation of yet unrecognized differences between
normal and tumor cells with respect to propagation,
evolution and development of resistance to conventional
treatments [65]. The discovery of neosis has identified
novel cellular targets, against which one can identify
novel neosis-specific molecular targets in order to
design anti-neotic agents or neosicides that will be more
specific in their action and do less harm to non diseased
cells. A judicial combination of senescent drugs with
efficient neosicides could further improve the status of
cancer control.
MC and role of MKs in cancer
According to the tenets of cancer biology, tumor cells
arise after about 13 mitotic divisions of the initiated cell
[66]. MKs, are rigorous quality control steps of mitosis
and function in preserving the fidelity and integrity of
DNA and allow mitosis to continue only with accurately
functioning DNA, spindle assembly, centrosome and
kinetochore thus preventing MC [67]. Malfunctioning of
MKs are intimately involved in the development of
Figure 2 Prerequisites for the onset of neosis and step-wise depiction of primary neosis (P/neosis) and secondary and tertiary neosis
(S/T neosis). When a normal diploid cell accumulates genetic mutation owing to exposure, either dies following apoptosis or necrosis or may
enter mitotic crisis and after repair again re-enters cell cycle or may become tetraploid after few hours or become polyploidy and succumb to
senescence or may circumvent senescence and divide by neosis. Neosis of non-viable NMCs may give rise to genetically viable daughter cells
‘Raju cells’ by P/neosis and further divide and re-divide by S/T neosis. The number of progenies may vary from one to infinite and differ from
NMCs and other daughter cells unlike conventional mode of division, mitosis. Number of surviving progenies depends on the ‘survival of the
fittest’.
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gical malignancies. MC is an event in which a cell is
destroyed during mitosis. This is believed to be caused
through apoptosis as a result of an attempt at aberrant
chromosome segregation early in mitosis, or as a result
of DNA damage later, during the metaphase/anaphase
transition. Cells which fail to go through a MC after
mitotic failures are likely to create aneuploid cells when
they later reproduce, posing a risk of oncogenesis,
potentially leading to cancer [67]. Hence MC is also in
the league of processes which participate in prevention
of cancer. MC which has been described as ‘Death
through a tragedy’ [68] is stimulated by ionizing radia-
tions (IR), chemotherapeutic drugs or hyperthermia and
is caused by malfunctioning of cell cycle checkpoints
and MKs. The normal choreography of the events in the
mitotic cell cycle gets disturbed and aneuploidy follows.
An aneuploid cell can be hyperaneuploid and may con-
tribute to tumorigenesis by an enhanced expression of
oncogenes or may be hypo-aneuploid and be liable for
tumorigenesis by a loss of heterozygosity of various
tumor suppressor genes [69].
MC shares several biochemical hallmarks of apoptosis,
in particular mitochondrial membrane permeabilization
and caspase activation [70] but is proposed to be funda-
mentally different from apoptosis [71]. Both senescence
and MC are important pathways that cause cell annihi-
lation upon chemotherapeutic intervention. The
mechanism and morphology of the deceased cells is
however different in both the cases. A tabular represen-
tation of the differences between MC and senescence is
given in Table 1.
Genetic checkpoint defects lead to syndromes that
demonstrate chromosomal instability, increased sensitiv-
ity to genotoxic stress and consequently cancer predis-
position. The detection of persistent MK over-
expression, particularly the Aurora kinase family, and
centrosome amplification in precursor/pre-malignant
stages, strongly correlate these molecular changes in
precipitating the aneuploidy seen in many human neo-
plasms [72]. The sustained over-expression and activity
of various members of the MK families, including Aur-
ora kinases (A, B, C), Polo-like (Plk1-4), and Nek
(NIMA1-11) in diverse human tumors strongly indicate
that these entities are closely involved in the develop-
ment of errors in centrosome duplication, chromosome
segregation, and cytokinesis.
MKs families
The focus of this section is on the different MKs
families. These kinases are modulated by de-novo synth-
esis, stability factors, phosphorylation, and ubiquitin-
dependent proteolysis. They, in turn, phosphorylate
innumerable centrosomal/mitotic protein substrates, and
have the ability to behave as oncogenes (i.e. Aurora-A,
Plk-1), providing a compelling link between errors in
mitosis and oncogenic processes [73]. Additionally, dys-
regulation of MKs have been linked with improper cell
cycle progression both in vitro and in vivo. Without get-
ting into the basics of MKs, the main pre-clinical and
clinical studies concerning MK inhibitors currently
under investigation are reported and important consid-
erations for their future development are discussed.
Here is given a representation of kinases in different
phases of cell cycle (Additional File 1: Table S1).
Cyclin dependent kinases 1 (Cdk1)
Cdk1 is vital participant in the mitotic cell cycle. Mitosis
begins and ends with the activity of cdk1 with binding
partner cyclin B1. First studied in fission yeast (Sacchar-
omyces cerevesiae), Nurse [74] identified a gene that
controlled mitosis and named it cdk1 or cdc2. Studies
have revealed that functional p53 protein may enhance
the anti-cancer activity of roscovitine (known cdk1 inhi-
bitor) that could be beneficial for anti-cancer therapy
[75]. Tumorigenecity mediated by p53 loss does not
require either Cdk2 or Cdk4, which necessitates consid-
eration of the use of broad spectrum cell cycle inhibitors
as a means of effective anti-Cdk cancer therapy [76].
Gartner et al have reported for the first time reported
an association of cyclins and Cdks with the microtubule
network by immunoelectron microscopy and immuno-
biochemical methods. Cyclins D, E, A and B as well as
Cdks 1, 2 and 4 were also found to be associated and
Table 1 Comparison between senescence and mitotic catastrophe
Characteristics Mitotic catastrophe Senescence
Definition Synonymous with ‘Terminal proliferation arrest’ may proceed with
apoptosis or necrosis depending on molecular profile of the cell
Synonymous with ‘Terminal growth arrest’ Cell
death in context of cancer
Biomarker Multinucleated giant cells, no specific in vitro and in vivo assay available SA-b galactosidase expression, detected by X-
gal staining
Morphology Aneuploidy, disrupted DNA index, micronuclei formation, nuclear envelope
lacking, nuclear fragmentation and uncondensed chromatin




Accelerated by G1, G2 and prophase checkpoint proteins (ATM, ATR, p53,
Chk2, Cdc25A, Cdc25B, Plk1 & 3)
Accelerated by telomere attrition, ras
mutations, inhibited by ALT or p53
Inducing agents Hyperthermia, IR, anti-cancer drugs interfering with DNA or microtubule
assembly
Spontaneous as a result of cumulative divisions
or challenged by oncogenic stimulus
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ciated protein tau [77]. Bailet et al [78] have highlighted
a new role for spleen tyrosine kinase (Syk) in regulating
cellular senescence and identify Syk-mediated senes-
cence as a novel tumor suppressor pathway, the inacti-
vation of which may contribute to melanoma
tumorigenicity. Study by Buchanan et al [79] on murine
adenocarcinoma mammary cells provided new clues
regarding the mechanism involved in the modulation of
mammary tumor cell growth and survival induced by
glypican-3. Gene expression profiling has generated
hypotheses that led to an increase in our knowledge of
the cellular effects of seliciclib (cdk inhibitor) and could
provide potential pharmacodynamic or response biomar-
kers for use in animal models and clinical trials [80].
Another Cdk inhibitor SU9516 is over expressed in
HCT116 cells by the knockout of the p21
WAF1/CIP1 gene
which suppresses thymidylate synthase and enhances
chemosensitivity to 5-Flurouracil [81].
Check point kinases 1 (Chk1) and 2 (Chk2)
Chk1 and Chk2 are effector kinases in the cellular DNA
damage response and impairment of their function is
closely related to tumorigenesis. If DNA damage is
detected after S and before G2/M transition, ATM/ATR
is activated and phosphorylation of Chk1 and Chk2
occurs [82] leading to cell death during mitosis or MC.
Experiments have demonstrated that there are alternate
mechanisms for activating ATM that are both stress-
specific and independent of the presence of DNA breaks
[83]. The activation of the ATR-Chk1 pathway in
response to bifunctional DNA alkylator 1,3-bis(2-chlor-
oethyl)-1-nitrosourea (BCNU) treatment and the depen-
dency of this response on the DNA mismatch repair
capacity were investigated. Chk1 was found to be phos-
phorylated at serine 345 and exhibited increased kinase
activity. Si-RNA knockdown of ATR also reduced Chk1
phosphorylation following exposure to BCNU. However,
knockdown of ATM had no effect on the observed
Chk1 phosphorylation, suggesting that ATR was primar-
ily responsible for Chk1 activation [84].
Polo like kinases (Plk)
A family of serine/threonine kinases also designated as
tubulin-associated proteins actively participate during
mitosis and comprises four distinct members: Plk1
(Plk), Plk2 (Snk), Plk3 (Prk or Fnk) and Plk4 (Sak) [85]
each carrying out a multitude of distinct roles. Plk1 is
the most extensively characterized among the family
members, suggesting that the polo box domain of it
can provide an additional structural basis for discovery
of new anti-cancer drugs. It was also found out that
Plk1 is required for chromosomal DNA replication
under stressful conditions [86] and Plk3 is more potent
in inhibiting cell proliferation and inducing apoptosis
[87].
Plk1 gene expression is tightly regulated with mRNA
increase beginning in S phase and peak mRNA levels
detected at G2-M transitions and through mitosis [88].
RNA-interference -mediated depletion of Plk1 to deter-
mine its potential for sensitizing pancreatic tumor cells
to gemcitabine showed that small interfering RNA-
mediated knockdown of Plk1 caused cell cycle arrest at
G2/M and the reduction of cellular proliferation and
decreased cell viability and increased cellular apoptosis
[89]. Transcription of Plk1 is inhibited along with other
G2/M specific genes like cyclin B1, cyclin B2 and
cdc25B by inhibition of Nuclear Factor kappa B at G2-
M phases [90]. Studies define and illuminate a late mito-
tic function of Plk1 that it is obligatory in the position-
ing and recruitment of Rho guanine nucleotide
exchange factor (RhoGEF) Ect2 to the central spindle
and abolishing RhoA GTPase localization to the equa-
torial cortex, and suppressing cleavage furrow formation
and cell division [91]. Increased plk-1 gene and protein
perhaps play a key role in abnormal proliferation of
acute leukemia cells and correlate with the malignancy
of leukemia [92] prostate carcinoma, [93] and gastric
carcinoma [94]. Snk/Plk2 is transcriptionally down-regu-
lated in B-cell neoplasms [95] and consequently pro-
vides a potential mechanistic basis underlying the strong
selective pressure for abrogation of Plk2 function in B-
cell neoplasia. Plk3 has been shown to catalyse the
priming of Cdc25A by phosphorylated glycogen synthase
kinase-3b (GSK-3b) and observations indicate that GSK-
3b inactivation may account for Cdc25A overproduction
in a subset of human tumors [96]. LFM-A13 (alpha-
cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)
propenamide) has recently been identified as an inhibi-
tor of Plks and markedly enhances the anti-cancer activ-
ity of paclitaxel [97] with anti-proliferative activity
against human breast cancer [98].
Aurora kinases
Aurora kinases namely, Aurora A(Aurora 2), Aurora B
(Aurora 1) and Aurora C(Aurora 3) are serine/threonine
kinases also known as tubulin-associated proteins [99]
which are expressed only in actively dividing cells and
their increase is a factor of bad prognosis in cancer.
Side effects, dosing and tolerability of inhibitors have
been discussed in great length by Pinel et al [100] and
enzymatic characterization of GSK1070916, a potent
and selective Aurora-B/Aurora-C inhibitor was done
and compared with other Aurora inhibitors AZD1152
and VX-680 [101], GSK1070916 was found to exert a
more prevailing inhibitory effect due to a slow rate of
dissociation from the Aurora-B & C enzymes. Detailed
kinetic analyses of two isogenic cell lines differing in
p53 function and have been compared with the effects
of ZM447439 and VE-465 to describe several mechan-
isms explaining how cells may evade killing by Aurora
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netochoric rings of MCAK and Aurora-B define a novel
transient centromere domain at least in mouse chromo-
somes during meiosis and also its functions have been
illustrated by Parra et al [103].
Bub related kinases (Bub family)
The Bub family of kinases constitutes members that are
concerned with spindle assembly functioning and APC/
C regulation. In one of the studies p53 was sustained to
express in K562 leukemic cells after being infected by
recombinant adenoviruses carrying the wt-p53 gene and
it was shown that wt-p53 can suppress excessive replica-
tion of centrosomes and may contribute to the upregu-
lation of Gadd45a and BubR1 protein expression as well
as the downregulation of Aurora A protein expression
[104]. A novel study reports that Ajuba, a microtubule-
associated protein collaborates with Aurora B and
BubR1 at the metaphase-anaphase transition and
ensures proper chromosome segregation[105].
Never in mitosis A- Related kinase (NIMA, Nek, Nrk)
The Nek or Nrk related kinase family are essential MKs
first described in the filamentous fungus Aspergillus
nidulans [106] containing 11 members (Nek1, 2, 3, 6, 7,
8, 9, and 11 are prominent) [107]. Nek1 is involved
early in the DNA damage sensing/repair pathway after
IR and G(1)-S-phase checkpoint control can be rescued
by ectopically over-expressing wild-type Nek1. More-
over, in cells without functional Nek1, DNA is not
repaired properly, double-stranded DNA breaks persist
long after low dose IR, and excessive numbers of chro-
mosome breaks are observed [108]. Recently, studies
have explicated that ciliary localization of Nek8 in a
subset of ureteric-bud-derived kidney tubules is essential
for maintaining the integrity of those tubules in the
mammalian kidney [109].
MKs and their role in cancer control- In a nutshell
As current cancer therapies are still in their infancy and
are not able to fulfill the expectations of cancer control,
strategies targeting mitotic regulators could be a poten-
tially pragmatic option, which may improve the thera-
peutic index when used either alone or in combination
with current anti-cancer antidotes. The uniqueness of
MKs lies in the fact that they are expressed in actively
duplicating cells and not in differentiated cells further
make it important targets against cancer cells. Targeting
MKs would aid us in understanding the mechanism of
chemo-resistance. The research efforts to examine the
role of MKs and mitotic signaling pathways are, how-
ever, in its beginning. By presenting an overview of reg-
ulation of MKs in this review, we open promising
avenues in designing novel therapeutic approaches in
curbing cancer. Simultaneously, we also present the
rationale for these kinases as an anti-cancer target.
Hence, more concern needs to be laid on in vivo work
to understand the role of MKs and their utility as tar-
gets before we can actually embark on translational stu-
dies in human.
Conclusions and future connotations
Cancer is a global health problem and various treatment
strategies are premeditated for curbing this deadly bio-
medical manifestation. Cells continuously encounter
DNA damage caused either by damaging agents, includ-
ing oxygen radicals and DNA replication errors caused
by stalled replication forks, or by extracellular environ-
ments such as ultraviolet or IR. The cellular response to
radiation or chemicals is complex and may lead to dif-
ferent biological outcomes. Senescence, MC, necrosis,
apoptosis and autophagy are such mechanisms out of
which the two former mechanisms have been discussed
in this review.
The physiological phenomenon of senescence is sti-
mulated by ras/raf activity, telomere attrition and p53.
Cellular senescence is a persistently growth-arrested
phenotype in normal and transformed cells which may
be beneficial when used to target the proliferation of
tumor cells or during organogenesis or wound healing.
It is well known that cancer risk rises exponentially with
age fuelled by somatic mutations. Senescence leads to
altered expression of genes (cell division control, cell
structure and metabolism) and imparts resistance to
cells towards apoptosis apart from actively secreting
inflammatory cytokines, proteinases and growth factors.
Keeping all these aspects about this mechanism in
mind, we can design novel treatment tactics in curbing
cancer. The discovery of neosis has identified novel cel-
lular targets, against which one can identify novel neo-
sis-specific molecular targets in order to design anti-
neotic agents or neosicides that will be effective against
many tumor types and theoretically be expected to have
a prophylactic action against multiple primary cancer
growths.
Discussing the regulation of MKs, we open promising
avenues in designing novel biomarkers for novel unex-
plored targets and present the rationale for these kinases
as an anti-cancer target. More in vivo work needs to be
undertaken to understand the role of MKs and their
prospective as cellular targets before translational stu-
dies can be performed in humans. Several key works
using clinical samples strongly suggest that point muta-
tions of the checkpoint genes contribute to malignant
transformation and genetic instability in cancer cells.
However, the exact role of DNA damage checkpoints in
the prevention of human carcinogenesis should be re-
evaluated. The spindle checkpoint inhibits the ubiquitin
ligase activity of the anaphase-promoting complex or
cyclosome (APC/C), which is essential for mitotic pro-
gression, until spindles are properly attached to all
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segregation. Because in a large proportion of tumors,
cell cycle checkpoints are compromised and apoptotic
pathways frequently suppressed, tumor cells preferen-
tially execute this mitotic mode of cell death after treat-
ment with DNA damaging regimens. A judicial
combination of anti-neosicides and anti-mitotic agent
may increase the therapeutic ratio under clinical set-
tings. Moreover, results of recent important research
work on senescence and MC can lay foundation of
other experiments targeting different cancers for testing
efficacy of already tested drugs and on some cancers for
different drugs sharing similarities in chemical and phy-
sical properties with known drugs.
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